Russell Investments Group Ltd. Has $502,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) (2025)

Russell Investments Group Ltd. raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 539.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 53,282 shares of the biopharmaceutical company’s stock after purchasing an additional 44,945 shares during the period. Russell Investments Group Ltd.’s holdings in Amicus Therapeutics were worth $502,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. HealthInvest Partners AB grew its holdings in Amicus Therapeutics by 18.6% during the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock valued at $3,076,000 after purchasing an additional 51,368 shares during the period. Tempus Wealth Planning LLC bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at $259,000. Intech Investment Management LLC raised its stake in Amicus Therapeutics by 59.7% during the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock worth $1,175,000 after buying an additional 46,633 shares during the period. Norges Bank bought a new position in Amicus Therapeutics during the fourth quarter worth about $29,033,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Amicus Therapeutics by 35.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company’s stock worth $2,850,000 after purchasing an additional 79,602 shares during the period.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $7.09 on Thursday. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -39.37, a PEG ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a fifty-two week low of $6.20 and a fifty-two week high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a fifty day moving average price of $8.26 and a 200-day moving average price of $9.44.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on FOLD. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company lowered their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Read Our Latest Stock Report on FOLD

Amicus Therapeutics Company Profile

(Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Recommended Stories

• Five stocks we like better than Amicus Therapeutics
• 2 Fintech Stocks to Buy Now and 1 to Avoid
• Can IBM’s Q1 Earnings Spark a Breakout for the Stock?
• The Role Economic Reports Play in a Successful Investment Strategy
• S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?
• 3 REITs to Buy and Hold for the Long Term
• Fundamentally Sound, These 5 Stocks Sold Off Anyway

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.